The Medical Letter on Drugs and Therapeutics
Minocycline Foam (Zilxi) for Rosacea
November 16, 2020 (Issue: 1611)The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi – Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer...more
- JQ Del Rosso et al. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol 2019; 12:17.
- Drugs for rosacea. Med Lett Drugs Ther 2016; 58:16.
- EJ van Zuuren et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 2019; 181:65.
- Oxymetazoline cream (Rhofade) for rosacea. Med Lett Drugs Ther 2017; 59:84.
- Brimonidine gel (Mirvaso) for rosacea. Med Lett Drugs Ther 2013; 55:82.
- Ivermectin cream (Soolantra) for rosacea. Med Lett Drugs Ther 2015; 57:51.
- D Thiboutot et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2020; 82:1501.
- LS Gold et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol 2020; 82:1166.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.